Journal of Clinical & Experimental Pathology
Open Access

Short Communication

Microsatellite Instability (MSI) Testing in Extra-colonic Tumors

University of Oklahoma Health Sciences Center, Oklahoma City, OK USA

*Corresponding Author:

Sanam Husain
University of Oklahoma Health Sciences Center
Oklahoma City, OK USA
Tel: 405-973-7527
E-mail: sanamhusain@ouhsc.edu

Received date: February 05, 2015, Accepted date: March 11, 2015, Published date: March 15, 2015

Citation: Husain S, Hassell LA (2015) Microsatellite Instability (MSI) Testing in Extra-colonic Tumors. J Clin Exp Pathol 5:221. doi: 10.4172/2161-0681.1000221

Copyright: © 2015 Husain S, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Faulty DNA repair due to defects in the mismatch repair genes results in microsatellite instability (MSI). Microsatellites are short tandem repeats that are present throughout the genome and are sensitive to errors during the cell cycle. Malfunctioning of the DNA repair mechanisms many occur as a result of germ line mutations in the MMR genes (MLH1, MSH2, PMS2 and MSH6) as in the autosomal dominant disorder Hereditary non-polyposis syndrome (HNPCC), also known as Lynch syndrome (LS) or due to hypermethylation of the MLH1 gene. LS is associated with Colorectal carcinoma (CRC) and extra-colonic malignancies including tumors of the endometrium, ovary, pancreas, urinary bladder, stomach, skin, biliary tract and the central nervous system. Early identification and management of such patients and their family members can significantly reduce morbidity and mortality associated with such tumors. Current literature suggests that MSI testing is important not only in the genetic context, but it also has prognostic and predictive value, as has been shown in treatment of CRC. Initial screening mechanisms such as the Amsterdam criteria and Bethesda guidelines were based on personal and family history. Since then various clinical prediction models have been developed that utilize clinical and pathologic features in the risk assessment of patients with MMR deficiency. However, due to the limitations in these screening methods, many institutions are moving towards universal screening of patients with CRC and endometrial carcinomas.In this review, we outline the rationale for and current methods of testing for MSI, along with their relative merits, and discuss the thorny question of screening criteria and who should be screened

Keywords